Sadness and broken hearts: Neurohumoral mechanisms and co-morbidity of ischemic heart disease and psychological depression

Journal of Physiology and Pharmacology

Volumn 57, Issue SUPPL. 11, 2006, Pages 5-29

  Johnson, Alan Kim ^a,c   Grippo, A J ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c E11 SSH   (United States)

Author keywords

Anhedonia; Chronic mild stress model of depression; Hypothalamic pituitary adrenal axis; Myocardial infarction induced model of heart failure; Pro inflammatory cytokines; Renin angiotensin aldosterone; Tumor necrosis factor (TNF)

Indexed keywords

ALDOSTERONE; ALPHA INTERFERON; ANTIDEPRESSANT AGENT; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; DEOXYCORTICOSTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; ETANERCEPT; FLUOXETINE; HUMORAL ANTIBODY; INTERLEUKIN 1; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PAROXETINE; RESERPINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC SYSTEM; ALTERNATIVE HYPOTHESIS; ANHEDONIA; CARDIOMYOPATHY; CARDIOTOXICITY; CHRONIC STRESS; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CYTOKINE RELEASE; DEPRESSION; DISEASE ASSOCIATION; EMOTIONAL DISORDER; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; ISCHEMIC HEART DISEASE; MAJOR DEPRESSION; MOTOR ACTIVITY; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VALVULAR HEART DISEASE;

ANIMALS; BEHAVIOR, ANIMAL; CHRONIC DISEASE; CORTICOTROPIN-RELEASING HORMONE; CYTOKINES; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; HEART FAILURE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MYOCARDIAL ISCHEMIA; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; STRESS, PSYCHOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34147161650     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (114)

1. Mathers CD, Loncar D. Updated Projections of Global Mortality and Burden of Disease, 2002-2030: Data Sources, Methods and Results. Geneva, World Health Organization. http://www.who.int/healthinfo/statistics/bodprojectionspaper.pdf, 2005.
2. Writing Committee for the ENRICHD Investigators. Effects of treating depression and low perceived social support on clinical events after myocardial infarction. JAMA 2003; 289: 3106-3116.
3. Dalack GW, Roose SP. Perspectives on the relationship between cardiovascular disease and affective disorder. J Clin Psychiatry 1990; 51 Suppl: 4-9; discussion 10-1.
4. Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998; 155: 4-11.
5. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998; 55: 580-592.
6. Nemeroff CB, Musselman DL, Evans DL. Depression and cardiac disease. Depress Anxiety 1998; 8 Suppl 1: 71-79.
7. Lesperance F, Frasure-Smith N, Talajic M. Major depression before and after myocardial infarction: its nature and consequences. Psychosom Med 1996; 58: 99-110.
8. Schleifer SJ, Macari-Hinson MM, et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989; 149: 1785-1789.
9. Freedland KE, Rich MW, Skala JA, Carney RM, Dávila-Román VG, Jaffe AS. Prevalence of depression in hospitalized patients with congestive heart failure. Psychosom Med 2003; 65: 119-128.
10. Carney RM, Rich MW, Freedland KE, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988; 50: 627-633.
11. Barefoot JC, Helms MJ, Mark DB, et al. Depression and long-term mortality risk in patients with coronary artery disease. Am J Cardiol 1996; 78: 613-617.
12. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993; 270: 1819-1825.
13. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91: 999-1005.
14. Booth-Kewley S, Friedman HS. Psychological predictors of heart disease: a quantitative review. Psychol Bull 1987; 101: 343-362.
15. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 1996; 94: 3123-3129.
16. Freedland KE, Carney RM, Lustman PJ, Rich MW, Jaffe AS. Major depression in coronary artery disease patients with vs. without a prior history of depression. Psychosom Med 1992; 54: 416-421.
17. National Institute of Mental Health. Depression Can Break Your Heart. Bethesda, National Institute of Mental Health. NIH Publication No. 01-4592. http://www.nimh.nih.gov/publicat/heartbreak.cfm, 2001.
18. Spiegel D. Cancer and depression. Br J Psychiatry 1996; Suppl 30: 109-116.
19. th Edition, Text Revision. Washington, D.C., American Psychiatric Association, 2000.
20. Grippo AJ, Johnson AK. Biological mechanisms in the relationship between depression and heart disease. Neurosci Biobehav Rev 2002; 26: 941-962.
21. Holsboer F. Neuroendocrinology of mood disorders. In Psychopharmacology: The Fourth Generation of Progress, FE Bloom, DJ Kupfer (eds). New York, Raven Press, 1995, pp. 957-969.
22. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509-522.
23. Coppen A. The biochemistry of affective disorders. Br J Psychiatry 1967; 113: 1237-1264.
24. Selye H. A syndrome produced by diverse nocuous agents. Nature 1936; 138: 32.
25. Weber B, Lewicka S, Deuschle M, Colla M, Vecsei P, Heuser I. Increased diurnal plasma concentrations of cortisone in depressed patients. J Clin Endocrinol Metab 2000; 85: 1133-1136.
26. Maes M, Lin A, Bonaccorso S, et al. Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. Acta Psychiatr Scand 1998; 98: 328-335.
27. Asnis GM, Halbreich U, Ryan ND, et al. The relationship of the dexamethasone suppression test (1 mg and 2 mg) to basal plasma cortisol levels in endogenous depression. Psychoneuroendocrinology 1987; 12: 295-301.
28. De Souza EB, Grigoriadis DE. Corticotropin-releasing factor: Physiology, pharmacology, and role in central nervous system and immune disorders. In Psychopharmacology: The Fourth Generation of Progress, FE Bloom, DJ Kupfer (eds). New York, Raven Press, 1995, pp. 505-517.
29. Nemeroff CB, Widerlov E, Bissette G, et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984; 226: 1342-1344.
30. Fisher LA. Corticotropin-releasing factor: endocrine and autonomic integration of responses to stress. Trends Pharmacol Sci 1989; 10: 189-193.
31. Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Brain Res Rev 1990; 15: 71-100.
32. Kirby LG, Rice KC, Valentino RJ. Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology 2000; 22: 148-162.
33. Rydin H, Verney EB. The inhibition of water-diuresis by emotional stress and by muscular exercise. Q J Exp Physiol 1938; 27: 343-374.
34. Selye H. Stress and disease. Science 1955; 122: 625-631.
35. Selye H, Hall CE, Rowley EM. Malignant hypertension produced by treatment with deoxycorticosterone acetate and sodium chloride. Can Med Assoc J 1943; 49: 88-92.
36. Selye H. Protection by a steroid-spirolactone against certain types of cardiac necroses. Proc Soc Exp Biol Med 1960; 104: 212-213.
37. Selye H. Production of hypertension and hyalinosis by desoxocortisone. Br Med J 1950; 1: 203-206.
38. Laragh JH, Angers M, Kelly WG, Liberman S. Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man. JAMA 1960; 174: 234-240.
39. Genest JE, Korw E, Nowaczynski W, Sandor T. Study of urinary adrenocortical hormones in human arterial hypertension. First International Congress of Endocrinology, Copenhagen, 1960.
40. Davis JO, Carpenter CCJ, Ayers CR, Holman JE, Bahn RC. Evidence for secretion of an aldosterone-stimulating hormone by the kidney. J Clin Invest 1961; 40: 684-696.
41. Germain L, Chouinard G. Treatment of recurrent unipolar major depression with captopril. Biol Psychiatry 1988; 23: 637-641.
42. Germain L, Chouinard G. Captopril treatment of major depression with serial measurements of blood cortisol concentrations. Biol Psychiatry 1989; 25: 489-493.
43. Zubenko GS, Nixon RA. Mood-elevating effect of captopril in depressed patients. Am J Psychiatry 1984; 141: 110-111.
44. Cohen LM, Anderson G, White RF, Griffing G, Melby J. Enalapril and hypertension. Am J Psychiatry 1984; 141: 1012-1013.
45. Deicken RF. Captopril treatment of depression. Biol Psychiatry 1986; 21: 1425-1428.
46. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657-1664.
47. Giardina WJ, Ebert DM. Positive effects of captopril in the behavioral despair swim test. Biol Psychiatry 1989; 25: 697-702.
48. Martin P, Massol J, Scalbert E, Puech AJ. Involvement of angiotensin-converting enzyme inhibition in reversal of helpless behavior evoked by perindopril in rats. Eur J Pharmacol 1990; 187: 165-170.
49. Okuyama S, Sakagawa T, Sugiyama F, Fukamizu A, Murakami K. Reduction of depressive-like behavior in mice lacking angiotensinogen. Neurosci Lett 1999; 261: 167-170.
50. Murck H, Held K, Ziegenbein M, Kunzel H, Koch K, Steiger A. The renin-angiotensin-aldosterone system in patients with depression compared to controls - a sleep endocrine study. BMC Psychiatry 2003; 3: 15.
51. Emanuele E, Geroldi D, Minoretti P, Coen E, Politi P. Increased plasma aldosterone in patients with clinical depression. Arch Med Res 2005; 36: 544-548.
52. Malinow KC, Lion JR. Hyperaldosteronism (Conn's disease) presenting as depression. J Clin Psychiatry 1979; 40: 358-359.
53. Khurshid KA, Weaver ME. Conn's syndrome presenting as depression. Am J Psychiatry 2005; 162: 1226.
54. Enya M, Kanoh Y, Mune T, et al. Depressive state and paresthesia dramatically improved by intravenous MgSO4 in Gitelman's syndrome. Intern Med 2004; 43: 410-414.
55. Fletcher AJ, Standen SM. A multi-centre study of potassium deficiency in the elderly. Curr Med Res Opin 1973; 1: 584-590.
56. Kronfol Z, Silva J, Jr., Greden J, Dembinski S, Gardner R, Carroll B. Impaired lymphocyte function in depressive illness. Life Sci 1983; 33: 241-247.
57. Irwin M, Gillin JC. Impaired natural killer cell activity among depressed patients. Psychiatry Res 1987; 20: 181-182.
58. Kronfol Z, House JD. Lymphocyte mitogenesis, immunoglobulin and complement levels in depressed patients and normal controls. Acta Psychiatr Scand 1989; 80: 142-147.
59. Lieb J, Karmali R, Horrobin D. Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins Leukot Med 1983; 10: 361-367.
60. Smith RS. The macrophage theory of depression. Med Hypotheses 1991; 35: 298-306.
61. Yirmiya R, Weidenfeld J, Pollak Y, et al. Cytokines, "depression due to a general medical condition," and antidepressant drugs. In Cytokines, Stress, and Depression, R Dantzer, EE Wollman, R Yirmiya (eds). New York, Kluwer Academic/Plenum, 1999, pp. 283-316.
62. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961-966.
63. Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 1998; 62: 583-606.
64. Yirmiya R, Pollak Y, Morag M, et al. Illness, cytokines, and depression. Ann N Y Acad Sci 2000; 917: 478-487.
65. Parmley WW. Neuroendocrine changes in heart failure and their clinical relevance. Clin Cardiol 1995; 18: 440-445.
66. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-254.
67. Fyhrquist F, Metsarinne K, Tikkanen I. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens 1995; 9 Suppl 5: S19-S24.
68. Johnson AK, Thunhorst RL. The neuroendocrinology of thirst and salt appetite: visceral sensory signals and mechanisms of central integration. Front Neuroendocrinol 1997; 18: 292-353.
69. De Nicola AF, Seltzer A, Tsutsumi K, Saavedra JM. Effects of deoxycorticosterone acetate (DOCA) and aldosterone on Sar1-angiotensin II binding and angiotensin-converting enzyme binding sites in brain. Cell Mol Neurobiol 1993; 13: 529-539.
70. Wang W, McClain JM, Zucker IH. Aldosterone reduces baroreceptor discharge in the dog. Hypertension 1992; 19: 270-277.
71. Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993; 33: 40-45.
72. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981; 91: 457-465.
73. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78: 902-907.
74. Schwinger RH. (The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study) in German. Dtsch Med Wochenschr 1999; 124: 987-988.
75. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
76. Dibbs Z, Kurrelmeyer K, Kalra D, et al. Cytokines in heart failure: pathogenetic mechanisms and potential treatment. Proc Assoc Am Physicians 1999; 111: 423-428.
77. Nozaki N, Yamaguchi S, Shirakabe M, Nakamura H, Tomoike H. Soluble tumor necrosis factor receptors are elevated in relation to severity of congestive heart failure. Jpn Circ J 1997; 61: 657-664.
78. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103: 2055-2059.
79. Frangogiannis NG, Burns AR, Michael LH, Entman ML. Histochemical and morphological characteristics of canine cardiac mast cells. Histochem J 1999; 31: 221-229.
80. Das UN. Free radicals, cytokines and nitric oxide in cardiac failure and myocardial infarction. Mol Cell Biochem 2000; 215: 145-152.
81. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002; 53: 31-47.
82. Ferrari R. The role of TNF in cardiovascular disease. Pharmacol Res 1999; 40: 97-105.
83. Morimoto K, Morimoto A, Nakamori T, Tan N, Minagawa T, Murakami N. Cardiovascular responses induced in free-moving rats by immune cytokines. J Physiol (Lond) 1992; 448: 307-320.
84. Saindon CS, Blecha F, Musch TI, Morgan DA, Fels RJ, Kenney MJ. Effect of cervical vagotomy on sympathetic nerve responses to peripheral interleukin-1beta. Auton Neurosci 2001; 87: 243-248.
85. Bozkurt B, Kribbs SB, Clubb FJ, Jr., et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97: 1382-1391.
86. Antonipillai I, Wang Y, Horton R. Tumor necrosis factor and interleukin-1 may regulate renin secretion. Endocrinology 1990; 126: 273-278.
87. Bataillard A, del Rey A, Klusman I, Arditi GM, Besedovsky HO. Interleukin-1 stimulates aldosterone secretion: involvement of renin, ACTH, and prostaglandins. Am J Physiol 1992; 263: R840-R844.
88. Gurantz D, Cowling RT, Villarreal FJ, Greenberg BH. Tumor necrosis factor-alpha upregulates angiotensin II type 1 receptors on cardiac fibroblasts. Circ Res 1999; 85: 272-279.
89. Bryant D, Becker L, Richardson J, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1998; 97: 1375-1381.
90. Lisman KA, Stetson SJ, Koerner MM, Farmer JA, Torre-Amione G. Managing heart failure with immunomodulatory agents. Cardiol Clin 2001; 19: 617-625.
91. Katz RJ. Animal model of depression: pharmacological sensitivity of a hedonic deficit. Pharmacol Biochem Behavior 1982; 16: 965-968.
92. Willner P, Sampson D, Papp M, Phillips G, Muscat R. Animal models of anhedonia. Anxiety, Depression, and Mania. In Animal Models of Psychiatric Disorders, P Soubrie (ed.) Basel, Karger 1991, pp. 71-99.
93. Loas G. Vulnerability to depression: a model centered on anhedonia. J Affect Disord 1996; 41: 39-53.
94. Moreau JL, Jenck F, Martin JR, Mortas P, Haefely WE. Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmentum self-stimulation behavior in rats. Eur Neuropsychopharmacol 1992; 2: 43-49.
95. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 1987; 93: 358-364.
96. Muscat R, Papp M, Willner P. Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology (Berl) 1992; 109: 433-438.
97. Solberg LC, Horton TH, Turek FW. Circadian rhythms and depression: effects of exercise in an animal model. Am J Physiol Regul Integr Comp Physiol 1999; 276: R152-R161.
98. Grippo AJ, Moffitt JA, Johnson AK. Cardiovascular alterations and autonomic imbalance in an experimental model of depression. Am J Physiol Regul Integr Comp Physiol 2002; 282: R1333-R1341.
99. Grippo AJ, Beltz TG, Johnson AK. Behavioral and cardiovascular changes in the chronic mild stress model of depression. Physiol Behav 2003; 78: 703-710.
100. Grippo AJ, Santos CM, Johnson RF, et al. Increased susceptibility to ventricular arrhythmias in a rodent model of experimental depression. Am J Physiol Heart Circ Physiol 2004; 286: H619-H626.
101. Grippo AJ, Francis J, Beltz TG, Felder RB, Johnson A.K. Neuroendocrine and cytokine profile of chronic mild stress-induced anhedonia. Physiol Behav 2005; 84: 697-706.
102. Grippo AJ, Beltz TG, Weiss RM, Johnson AK. The effects of chronic fluoxetine treatment on chronic mild stress-induced cardiovascular changes and anhedonia. Biol Psychiatry 2006; 59: 309-316.
103. Krittayaphong R, Cascio WE, Light KC, et al. Heart rate variability in patients with coronary artery disease: differences in patients with higher and lower depression scores. Psychosom Med 1997; 59: 231-235.
104. Odemuyiwa O, Malik M, Farrell T, Bashir Y, Poloniecki J, Camm J. Comparison of the predictive characteristics of heart rate variability index and left ventricular ejection fraction for all-cause mortality, arrhythmic events and sudden death after acute myocardial infarction. Am J Cardiol 1991; 68: 434-439.
105. Kleiger RE, Miller JP, Bigger JT, Jr., Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256-262.
106. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl) 1997; 134: 319-329.
107. Glassman AH. Cardiovascular effects of antidepressant drugs: updated. Int Clin Psychopharmacol 1998; 13 Suppl 5: S25-S30.
108. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EG, Bigger JT, Jr. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998; 155: 660-665.
109. Grippo AJ, Francis J, Weiss RM, Felder RB, Johnson AK. Cytokine mediation of experimental heart failure-induced anhedonia. Am J Physiol Regul Integr Comp Physiol 2003; 284: R666-R673.
110. Anisman H, Kokkinidis L, Borowski T, Merali Z. Differential effects of interleukin (IL)-1beta, IL-2 and IL-6 on responding for rewarding lateral hypothalamic stimulation. Brain Res 1998; 779: 177-187.
111. Francis J, Weiss RM, Wei SG, Johnson AK, Felder RB. Progression of heart failure after myocardial infarction in the rat. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1734-R1745.
112. Morris MJ, Na ES, Grippo AJ, Johnson AK. The effects of deoxycorticosterone-induced sodium appetite on hedonic behaviors in the rat. Behav Neurosci 2006; 120: 571-579.
113. Grippo AJ, Na ES, Johnson RF, Beltz TG, Johnson AK. Sucrose ingestion elicits reduced Fos expression in the nucleus accumbens of anhedonic rats. Brain Res 2004; 1019: 259-264.
114. Grippo AJ, Moffitt JA, Beltz TG, Johnson AK. Reduced hedonic behavior and altered cardiovascular function induced by mild sodium depletion in rats. Behav Neurosci 2006; 99: 758-766.